Hyperkalemia Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Hyperkalemia Drugs Market is segmented By Disease Type (Chronic hyperkalemia, Acute hyperkalemia), By Drug Type (Renin-angiotensin-aldosterone system inhibitors, ACE-inhibitors, Beta-blockers, Non-steroidal anti-inflammatory drugs, Others), By Distribution Channel (Retail pharmacies & drugstores, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Hyperkalemia Drugs Market Size

Global Hyperkalemia Drugs Market reached US$  million in 2023 and is expected to reach US$   million by 2031 growing at a CAGR during the forecast period 2024-2031.

Hyperkalemia is a condition with too much potassium in the blood above the average level. Hyperkalemia happens if the kidneys do not work well which leads to life-threatening heart rhythm changes or cardiac arrhythmias, and paralysis. Other causes include Addison's disease, destruction of red blood cells due to severe injury and burns. 

Drugs such as amoxicillin and heparin that prevent the kidneys from losing enough potassium leads to hyperkalemia. Kidney disease is the most common cause of hyperkalemia. Treatment includes medication and dialysis, which filters potassium from your blood. Water pills (diuretics) remove potassium via the urinary tract.

Hyperkalemia Drugs Market Summary

For more insights Request Free Sample

Hyperkalemia Drugs Market Dynamics

Increasing clinical trials

Hyperkalemia drugs are tested for efficacy and safety through various clinical trials. Though it is caused by multiple factors, medications like sodium zirconium have shown efficacy in specific clinical trials. These drugs are useful for the treatment of hyperkalemia that is arised due to chronic kidney disease (CKD), and other kidney disorders. 

AstraZeneca is conducting phase 3 clinical trials to assess safety and efficacy of sodium zirconium cyclosilicate in Pediatric Patients With Hyperkalaemia (PEDZ-K). The start date is April 2, 2019.

Vifor Fresenius Medical Care Renal Pharma collaborated with Tigermed Consulting Co., Ltd to conduct phase 3 clinical trials to the efficacy and safety of Patiromer in Chinese Subjects (Patiromer JADE). The start date is February 10, 2022.

AstraZeneca is conducting phase 4 clinical trial to compare Sodium Zirconium cyclosilicate to standard of care (SoC) in patients with chronic kidney disease (CKD). The start date is March 24, 2022.

Side effects of sodium polystyrene sulfonate

Diagnosis of hyperkalemia is difficult as it doesn't show symptoms. However, hyperkalemia drugs cause adverse effects after use in chronic kidney disease patients. Sodium polystyrene sulfonate has several side effects, such as loss of appetite, nausea, colonic necrosis, seizures, muscle weakness, and abdominal pain. Excessive usage of SPS can lead to sodium overload and fluid retention. People with abnormal bowel obstruction are not recommended to use SPS.

Hyperkalemia Drugs Market Segment Analysis

The global hyperkalemia drugs market is segmented based on disease type, drug type, route of administration,  distribution channel and region.

The sodium zirconium cyclosilicate segment accounted for approximately 32.5% of the market share 

Sodium zirconium cyclosilicate, which treats hyperkalemia, is expected to hold the largest market share as there are increased clinical trials for the safety and efficacy of the drug in treating hyperkalemia more efficiently than other drugs. 

AstraZeneca is conducting phase 2 clinical trials to demonstrate the efficacy and safety of Sodium Zirconium Cyclosilicate (SZC) in optimizing MRA (Mineralocorticoid receptor antagonists) treatment of heart failure associated with hyperkalemia. The start date is September 1, 2021.

In January 2022, The National Institute of Health and Care Excellence (NICE) updated its guideline for AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) in chronic kidney disease (CKD)-related hyperkalemia (HK). In the United Kingdom, this updated recommendation will make it easier for patients to obtain medication outside hospitals.

Hyperkalemia Drugs Market Geographical Share

North America accounted for approximately 41.5% of the market share 

North America is expected to hold the largest market share due to the disease prevalence across the region. As there is a high prevalence of kidney-related diseases that cause hyperkalemia, a rise in the hyperkalemia drugs market is expected in the forthcoming period. 

According to the National Institute of Diabetes and Digestive and Kidney Diseases, 2023 issue, chronic kidney disease (CKD) affects more than 1 in 7 U.S. adults, an estimated 37 million Americans. Approximately 2 in 1,000 Americans are surviving with end-stage kidney disease (ESKD)

According to the National Center for Biotechnology Information, Chronic kidney disease (CKD) is a significant health concern affecting approximately 4 million Canadians and 11% to 13% of the population globally. The economic burden of chronic and end-stage kidney disease is high, costing Canada's national healthcare system more than $40 billion per year.

COVID-19 Impact Analysis

Covid 19 impacted drug delivery across the world. Due to the rise in COVID-19 cases, lockdowns were implemented, which halted the drug supply chain. There is a sharp shift in the focus in research and development towards the invention of vaccines for covid 19. Clinical trials were halted due to the severity of the situation worldwide. As hyperkalemia is sometimes non-symptomatic, the disease was left undiagnosed and untreated.

Hyperkalemia Drugs Market Companies

The major global players in the hyperkalemia drugs market include Pfizer Inc., scPharmaceuticals, Inc., Merck KGaA, Teva Pharmaceuticals USA, Inc., Camber Pharmaceuticals, Inc., Sarfez Pharmaceuticals, Inc., AstraZeneca, Vifor Pharma, Inc., Novo Nordisk A/S., and Eli Lilly and Company among others.

Key Developments

• AstraZeneca showcased five real-world evidence (RWE) studies from its industry-leading Cardiovascular, Renal, and Metabolism (CVRM) portfolio, reinforcing its commitment to advancing science in chronic kidney disease (CKD) and hyperkalemia (HK), at the National Kidney Foundation (NKF) Spring Clinical Meeting April 11-15, 2023.
• In April 2022, Vifor Pharma declared full results for phase IIIb DIAMOND trial of Veltassa in heart failure patients with either manifest hyperkalemia or a history of hyperkalemia while treated with renin-angiotensin-aldosterone system inhibitor (RAASi) therapy.

Why Purchase the Report?

• To visualize the global hyperkalemia drugs market segmentation based on disease type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of hyperkalemia drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global hyperkalemia drugs market report would provide approximately 69 tables, 75 figures, and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies